This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jean-François Vitoux, MD; Jean-Noël Fiessinger, MD; Martine Roncato, PhD; Jean-Marc Pernes, MD; Philippe Brenot, MD; Martine Aiach, PhD
Hôpital Broussais Paris

JAMA. 1988;259(8):1180-1181.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—Most authors agree with the necessity for long-term antithrombotic therapy after the short-term treatment of deep venous thrombosis (DVT) to prevent thrombus extension and thromboembolic phenomena. However, the duration of this treatment and the nature and dosage of the different drugs are still a matter of debate.^1-3 Some properties of low-molecular-weight heparin (LMWH), such as long half-life, good bioavailability, and the low incidence of induced thrombocytopenia, support its use as an alternative in the long-term treatment of DVT.

Study.

—Ten patients (mean age, 59 years) with proximal DVT were included in a prospective study. All the DVTs were recent, as assessed by history and clinical and angiographic criteria. Causes and locations of DVT were varied. Six involved the iliofemoral vein, three involved the superficial femoral vein, and three involved the popliteal vein. The mean ( ± SD) initial phle

bographic score, derived from Arnessen et al,⁴ . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?